FIELD: medicine; pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics and medicine, namely to treating COVID-19. Disclosed is use of 1-[2-(1-methylimidazol-4-yl)-ethyl]perhydroazine-2,6-dione or a pharmaceutically acceptable salt thereof for the treatment and/or prevention of mild COVID-19 disease, and symptoms.
EFFECT: use of the invention enables the effective treatment of mild COVID-19.
16 cl, 2 ex
Authors
Dates
2024-07-30—Published
2021-12-23—Filed